You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Does Foundayo™ (orforglipron) slow gastric emptying?
Orforglipron slows gastric emptying. The delay is largest after the first dose and diminishes over time.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Prescribing Information Related to Orforglipron's Effect on Gastric Emptying
- Published Literature Regarding the Effect of Incretin Analogues on Gastric Emptying
- Enclosed Prescribing Information
- References
Prescribing Information Related to Orforglipron's Effect on Gastric Emptying
Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist that binds to and activates the human GLP-1 receptor.1
Orforglipron delays gastric emptying. The delay is largest after the first dose and diminishes over time.1
Use of orforglipron has been associated with gastrointestinal adverse reactions, sometimes severe. Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.1
Orforglipron is not recommended in patients with severe gastroparesis.1
Potential Drug Interactions Due to Gastric Emptying Delay
Orforglipron delays gastric emptying and has the potential to affect the rate of absorption of other concomitantly administered oral drugs.1
The gastric emptying delay effect of orforglipron on maximum plasma concentration (Cmax) of acetaminophen was largest after the first dose of orforglipron 0.8 mg with acetaminophen Cmax decreased by 28%. The effect diminished after repeated dosing of orforglipron 17.2 mg.1
Orforglipron's Effect on Oral Contraceptives
Use of orforglipron may reduce the efficacy of oral hormonal contraceptives.1
Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with orforglipron and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.1
Pulmonary Aspiration During General Anesthesia or Deep Sedation
Orforglipron delays gastric emptying.1
There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.1
Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking orforglipron, including whether modifying preoperative fasting recommendations or temporarily discontinuing orforglipron could reduce the incidence of retained gastric contents.1
Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking orforglipron.1
Published Literature Regarding the Effect of Incretin Analogues on Gastric Emptying
The delay in gastric emptying following the administration of a GLP-1 receptor agonist is well recognized and has been hypothesized as one of the factors contributing to blood glucose, appetite, and food intake reduction.2-4
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- Flint A, Raben A, Ersbøll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25(6):781-792. https://doi.org/10.1038/sj.ijo.0801627
- Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530. https://doi.org/10.1155/2011/279530
- Smits MM, Tonneijck L, Muskiet MH, et al. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224-235. https://doi.org/10.1111/dom.12593
Date of Last Review: April 01, 2026